These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 32595092)

  • 21. Defining biochemical recurrence after radical prostatectomy and timing of early salvage radiotherapy : Informing the debate.
    Budäus L; Schiffmann J; Graefen M; Huland H; Tennstedt P; Siegmann A; Böhmer D; Budach V; Bartkowiak D; Wiegel T
    Strahlenther Onkol; 2017 Sep; 193(9):692-699. PubMed ID: 28470414
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Wrong to be Right: Margin Laterality is an Independent Predictor of Biochemical Failure After Radical Prostatectomy.
    Kang JJ; Reiter RE; Kummer N; DeKernion J; Steinberg ML; King CR
    Am J Clin Oncol; 2018 Jan; 41(1):1-5. PubMed ID: 26237192
    [TBL] [Abstract][Full Text] [Related]  

  • 23. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
    Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term outcomes after high-dose postprostatectomy salvage radiation treatment.
    Goenka A; Magsanoc JM; Pei X; Schechter M; Kollmeier M; Cox B; Scardino PT; Eastham JA; Zelefsky MJ
    Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):112-8. PubMed ID: 22300563
    [TBL] [Abstract][Full Text] [Related]  

  • 25. First Postprostatectomy Ultrasensitive Prostate-specific Antigen Predicts Survival in Patients with High-risk Prostate Cancer Pathology.
    Kang JJ; Reiter RE; Steinberg ML; King CR
    Eur Urol Oncol; 2018 Oct; 1(5):378-385. PubMed ID: 31158076
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome--results of a retrospective study.
    Wiegel T; Lohm G; Bottke D; Höcht S; Miller K; Siegmann A; Schostak M; Neumann K; Hinkelbein W
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1009-16. PubMed ID: 18963539
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ten-year disease progression and mortality rates in men who experience biochemical recurrence versus persistence after radical prostatectomy and undergo salvage radiation therapy: A post-hoc analysis of RTOG 9601 trial data.
    Sood A; Keeley J; Palma-Zamora I; Arora S; Dalela D; Olson P; Hanna R; Cotter D; Jeong W; Elshaikh M; Rogers CG; Peabody JO; Menon M; Abdollah F
    Urol Oncol; 2020 Jun; 38(6):599.e1-599.e8. PubMed ID: 32229186
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term results and predictive factors of three-dimensional conformal salvage radiotherapy for biochemical relapse after prostatectomy.
    Neuhof D; Hentschel T; Bischof M; Sroka-Perez G; Hohenfellner M; Debus J
    Int J Radiat Oncol Biol Phys; 2007 Apr; 67(5):1411-7. PubMed ID: 17275204
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Salvage radiation therapy improves metastasis-free survival for clinically aggressive and indolent prostate cancer recurrences after radical prostatectomy.
    Jackson WC; Johnson SB; Feng FY; Hamstra DA
    Am J Clin Oncol; 2015 Aug; 38(4):367-72. PubMed ID: 23822986
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictors of early, intermediate and late biochemical recurrence after minimally invasive radical prostatectomy in a single-centre cohort with a mean follow-up of 8 years.
    García-Barreras S; Nunes I; Srougi V; Secin F; Baghdadi M; Sánchez-Salas R; Barret E; Rozet F; Galiano M; Cathelineau X
    Actas Urol Esp (Engl Ed); 2018 Oct; 42(8):516-523. PubMed ID: 29606285
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Utilization of Salvage Radiation Therapy for Biochemical Recurrence After Radical Prostatectomy.
    Hawken SR; Spratt DE; Qi J; Linsell SM; Cher ML; Ghani KR; Miller DC; Montie JE; Morgan TM;
    Int J Radiat Oncol Biol Phys; 2019 Aug; 104(5):1030-1034. PubMed ID: 30682490
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prostate-specific antigen decline during salvage radiation therapy following prostatectomy is associated with reduced biochemical failure.
    Kabarriti R; Ohri N; Hannan R; Tishbi N; Baliga S; McGovern KP; Mourad WF; Ghavamian R; Kalnicki S; Guha C; Garg MK
    Pract Radiat Oncol; 2014; 4(6):409-14. PubMed ID: 25407863
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adjuvant radiation therapy is associated with better oncological outcome compared with salvage radiation therapy in patients with pN1 prostate cancer treated with radical prostatectomy.
    Tilki D; Preisser F; Tennstedt P; Tober P; Mandel P; Schlomm T; Steuber T; Huland H; Schwarz R; Petersen C; Graefen M; Ahyai S
    BJU Int; 2017 May; 119(5):717-723. PubMed ID: 27743493
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series.
    Gandaglia G; Fossati N; Karnes RJ; Boorjian SA; Colicchia M; Bossi A; Seisen T; Cozzarini C; Di Muzio N; Noris Chiorda B; Zaffuto E; Wiegel T; Shariat SF; Goldner G; Joniau S; Battaglia A; Haustermans K; De Meerleer G; Fonteyne V; Ost P; Van Poppel H; Montorsi F; Briganti A
    Eur Urol; 2018 Apr; 73(4):512-518. PubMed ID: 29229176
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The timing of salvage radiotherapy after radical prostatectomy: a systematic review.
    King CR
    Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):104-11. PubMed ID: 22795730
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adjuvant versus early salvage radiotherapy: outcome of patients with prostate cancer treated with postoperative radiotherapy after radical prostatectomy.
    Vogel MME; Kessel KA; Schiller K; Devecka M; Gschwend JE; Weichert W; Wilkens JJ; Combs SE
    Radiat Oncol; 2019 Nov; 14(1):198. PubMed ID: 31711524
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical Outcome of Salvage Radiotherapy for Locoregional Clinical Recurrence After Radical Prostatectomy.
    Lee SU; Cho KH; Kim JH; Kim YS; Nam TK; Kim JS; Cho J; Choi SH; Shim SJ; Kim JH; Chang AR
    Technol Cancer Res Treat; 2021; 20():15330338211041212. PubMed ID: 34806469
    [No Abstract]   [Full Text] [Related]  

  • 38. Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy.
    Oehus AK; Kroeze SGC; Schmidt-Hegemann NS; Vogel MME; Kirste S; Becker J; Burger IA; Derlin T; Bartenstein P; Eiber M; Mix M; la Fougère C; Belka C; Combs SE; Grosu AL; Müller AC; Guckenberger M; Christiansen H; Henkenberens C
    BMC Cancer; 2020 Apr; 20(1):362. PubMed ID: 32349700
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Radiotherapy after radical prostatectomy for prostate cancer: clinical outcomes and factors influencing biochemical recurrence.
    Fukuda I; Aoki M; Kimura T; Ikeda K
    Ir J Med Sci; 2023 Dec; 192(6):2663-2671. PubMed ID: 37097540
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of prostate-specific antigen persistence after radical prostatectomy on the efficacy of salvage radiotherapy in patients with primary N0 prostate cancer.
    Bartkowiak D; Siegmann A; Böhmer D; Budach V; Wiegel T
    BJU Int; 2019 Nov; 124(5):785-791. PubMed ID: 31220400
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.